Journal club Dr Eyad Al-Saeed Radiation Oncology 8-Sep-2007.

Slides:



Advertisements
Similar presentations
†Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2011 Incidence and Mortality Web-based Report. Atlanta (GA): Department.
Advertisements

Controversies in Breast Cancer Allan Arkush, DO, FACOS.
Breast cancer in pregnancy sadaf alipour assistant professor general surgeon tehran university of medical sciences.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
BREAST CANCER UPDATE DETECTION TO DIAGNOSIS
Do you know what ’ s in people ’ s head?. Brain tumors 72 male 72 male HPI: presents to E.R. with history of confusion, change of personality, left sided.
4.6 Assessment of Evaluation and Treatment 2013 Analytic Lung Cancer.
Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.
Update in the Management of Thyroid Neoplasms University of Washington
In The Nam of God.
THE CAUSES AND EFFECTS OF HAVING A BRAIN TUMOR BRAIN TUMOR RESEARCH By: Ari Thomas 11/19/14.
What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Breast Imaging Made Brief and Simple
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
Cancer Genetics. Issues Colorectal guidelines – Awaiting publication of coloproctologists guidance – SIGN / QIS update started Breast / ovarian – Breast.
BREAST CANCER OVERVIEW Polly Stephens, M.D.. BREAST ANATOMY.
GYN ONCOLOGY OBesity Project. “Obesity is linked as a cause of 20% of cancer deaths in women.”
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a.
The Value of Six Month Interval Imaging Following Benign Radiologic-Pathologic Concordant Minimally Invasive Breast Biopsy Manjoros DT, Collett AE, Alberty-Oller.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
LUNG CANCER Dr.Mohammadzadeh. Lung cancer is the leading cancer killer in the United States. Every year, it accounts for 30% of all cancer deaths— more.
Atoosa Adibi MD. Department of Radiology Isfahan University Of Medical Sciences.
MedPix Medical Image Database COW - Case of the Week Case Contributor: Russell A. Patterson Affiliation: Uniformed Services University.
A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases.
WORK UPS. Ultrasound method of choice for the differentiation of cysts from solid masses and for guidance in interventional procedures. Benign: – solid.
Failure of Treatment in Cervical Cancer Patients *Dr. Zohreh Yousefi fellow ship of gynecology oncology of Mashhad university Fatemeh Homaee, Marzieh.
Role of PCI in Small Cell Lung Cancer Dr. Litan Naha Biswas Apollo Gleanagles Hospital, Kolkata.
Clinical Trials Evaluating the Role of Sentinel Node Resection in Patients with Early-Stage Breast Cancer Krag DN et al. Proc ASCO 2010;Abstract LBA505.
(4) Radiation Therapy Oncology Group (RTOG)
Palliative Care Eyad Al-Saeed, MD,FRCPC Consultant Radiation Oncology Prince Sultan Hematology Oncology Center.
March 10, 2014 NURS 330 Human Reproductive Health.
Hanan.A.Eltyb Incidence Approximately 15% of bronchogenic carcinomas. In the year 2013, an estimated new cases will be diagnosed at USA.
Cancer Prevention Eyad Alsaeed, MD,FRCPC Consultant Radiation Oncology PSHOC KFMC.
In The Name of God BREAST IMAGING N. Ahmadinejad Medical Imaging Center TUMS.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Understanding Cancer and Related Topics
SMALL CELL LUNG CANCER 2007 BP HIGGINS MD FRCPC CFPRCC.
Campbell’s & Literature review. Campbell 9 th & 10 th edition Cytoreductive nephrectomy  Palliation for: 1. Severe bleeding. 2. Pain. 3. Paraneoplastic.
M ETHODS Median dose was 22Gy (range: ) in 1 to 5 fractions Median treatment volume was 12.6 cc (range: ). Assessed for eligibility.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. N. Perez-Staub, G. Lledo, F. Paye, B. Gayet, M. Flesch, A. Cervantes, A. Figer,
Anaplastic thyroid cancer based on ATA guideline for Management of Patients with ATC. Thyroid. 2012;22: R3 이정록.
N ENGL J MED 호흡기내과 R1 윤수진 SCREENING FOR OCCULT CANCER IN UNPROVOKED VENOUS THROMBOEMBOLISM.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Role of Radiation Therapy in Brain metastasis Bongkot Supawongwattana, M.D. Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang.
Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in
SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
BREAST BRACHYTHERAPY OUTCOMES EVALUATION Margaret Pierce DNP, APRN, BC University of Tennessee Knoxville, Tennessee.
Tumor Marker Phenotype Concordance in Second Primary Breast Cancer Monica Brown, MPH, PhD California Cancer Registry Mary Paré, RN, BS Sutter Cancer Center,
Surgery for Metastatic Brain Tumor from Breast Cancer
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
OPTIMAL STRATEGY FOR PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED STAGE SMALL CELL LUNG CANCER Patricia Tai 1, Avi Assouline 2,3, Kurian Joseph 4, Edward.
Application of the breast imaging reporting and data system final assessment system in sonography of palpable breast lesions and reconsideration of the.
Beyond breast specific—Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome Gaia Griguolo DiSCOG-University.
Instructor Kathleen Gamblin, RN, BSN, OCN Oncology Nurse Navigator
TMIST A Breast Cancer Screening Trial
Indications for Breast MR Imaging
Dr Amit Gupta Associate Professor Dept Of Surgery
But how to treat those with positive SLNB? Results and Discussion
A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)
Prevalence of Brain Metastases Immediately before Prophylactic Cranial Irradiation in Limited Disease Small Cell Lung Cancer Patients with Complete Remission.
Breast cancer pathway update – Primary care pathways event
Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?  Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,
Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise  Chad G. Rusthoven, MD, Brian.
Stamatia Destounis, MD, FACR, FSBI, FAIUM
Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer  Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,
Presentation transcript:

Journal club Dr Eyad Al-Saeed Radiation Oncology 8-Sep-2007

Prophylactic cranial Irradiation in Extensive Small Cell Lung Cancer ► Inclusion Criteria : ► Age ► PS (0 – 2) ► Documented extensive SCLC before starting CTR ► Response after 4 – 6 cycle ► Interval of no more than 5/52 between the last cycle of CT and Radiation ► No evidence of brain metastases ► No Hx of Rad to H/N area ► No Hx of CS use ► No Previous or other current cancer

► PCI :- ► 2 lateral fields ► Co, 4 – 18 MV ► Daily RX / 5 weeks ► Dose was 20Gy / 5–8 fx 24 Gy / 12 fx 24 Gy / 12 fx 25 Gy/ 10 fx 25 Gy/ 10 fx 30 Gy/ 10 –12 fx 30 Gy/ 10 –12 fx. Radiation started 4 – 6 weeks after CT

► Point in the study:- ► End Point : Development of symptomatic brain metastases including : ► 1- HA ► 2- N/V ► 3- cognitive or affective disturbance ► 4- Seizures ► 5- Focal neurological symptoms

Role of PCI ?? Role of PCI ?? The role of PCI in patient who do not have complete response to CTR is unclear - Usually they don’t have complete response

Characteristic of Patients: There were no significant differences between patients in the irradiation group and those in the control group in any category

Results - Patient in the irradiation group had a lower risk of symptomatic brain metastases - Cumulative risk of brain metastases within 1 year was : 14.6% in the irradiation group. 40.4% in the control group. - The 1 year survival rate was 27.1% in irradiation group and 13.3% in the control group.

Cumulative Incidence of Symptomatic Brain Metastases.

Disease-free Survival

Overall Survival

Conclusion: PCI reduce the incidence of symptomatic brain met and prolongs DFS + OS and prolongs DFS + OS

MRI Evaluation of the Contralateral Breast in Women With Recently Diagnosed Breast Cancer Aim of study: - ► ----To detect contralateral breast cancer by MRI and histological confirmed. ► ---- Prevent patient to undergo a second round of cancer therapy rather than a single round if DX had been made initially. a single round if DX had been made initially. ► ---- To detect SS, NPV, PPV value of MRI a/w positive biopsy.

Patient Eligibility:- 1 ) > 18 Y/O 2 ) DX of unilateral breast cancer within 60 days before MRI performed. performed. 3 ) Patient had normal clinical & Mammogram in the contralateral breast within 90 days before enrollment. breast within 90 days before enrollment.

Excluding Criteria:- 1 ) If patient had MRI within 12 months before enrollment 2 ) Pregnant. 3 ) Contraindication of MRI. 4 ) Dx > 60 days.

Characteristics of Eligible Patients:-

Results:- out of 969 patient 1) MRI detected clinically and mammographically occult breast cancer in the contralateral breast in 30 of 969 women who were enrolled in the study  3.1% 2) BX was performed on basis positive MRI finding in 121 of the 969 women ( 12.5%) ► 30  24.8% positive for Cancer  18 out of 30 specimens  positive for invasive cancer.  12 out of 30 specimens  positive in situ carcinoma. 3) Sensitivity of MRI in the contra lateral breast  91% 4) Specificity  88% 5) NPV of MRI  99%

Conclusion:- MRI can detect cancer in contra lateral breast that is missed by mammogram and clinical examination at the time of the initial breast cancer diagnosis.